Global Community

Palantir's Q2 2026 was genuinely extraordinary: revenue of $1.935 billion grew 93% year over year, US commercial revenue grew 149%, and the company raised full-year guidance to roughly $8.15 billion, about 82% growth. That part of the story is real and it is the reason to be interested.Read more

Rhythm Pharmaceuticals is turning a rare genetic obesity medicine into a broader set of uses, and early demand looks stronger than expected as more doctors start prescribing it. On top of that, recent deal activity in similar drug areas suggests the company could become more attractive to a buyer if it keeps executing.Read more

Catalysts The main catalyst for PetroTal is the restart of drilling at the Bretaña field. Production has fallen heavily over the last year.Read more

FreightCar America shifts production to a large, lower-cost factory in northern Mexico and now says the hard part of its turnaround is largely behind it. If demand stays steady and the company keeps cleaning up past financing baggage, it could keep taking customers from higher-cost rivals—but the earlier transition shows the risks if conditions change.Read more

Lucky Cement’s recent results look stronger than they first seem, driven by rising local demand and real cost cuts rather than one-off accounting boosts. With new capacity coming online overseas and earnings help from its power, chemicals, and auto businesses, the market may be underestimating how much runway it still has.Read more

A constructive long-term outlook supported by trend structure, key moving averages, and breakout potential. Overview Robo.ai (AIIO) has developed from a speculative micro-cap name into a more technically structured growth candidate.Read more

Novo Nordisk’s weight-loss medicines turn a diabetes specialist into a cultural and medical heavyweight, and the company now races to expand factories and develop the next wave of treatments. The bigger question is whether new rivals and tougher rules could slow the momentum—or whether this recent pullback is a rare chance to buy into a business with years of demand ahead.Read more

If gold prices rise a lot, STLLR Gold could look very different because its large gold resource base becomes far more valuable. The key question is whether investors treat it like a real producer with a value tied to what it can pull out of the ground—or just a pile of ounces on paper.Read more

Rigaku shifts from selling lab instruments to becoming a key supplier of tools chipmakers use to check and fine-tune ever-more complex chips. As big chip factories plan larger buildouts, this change could make Rigaku’s faster-growing semiconductor business matter far more than many investors expect.Read more